9
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT1D receptor agonists

&
Pages 581-593 | Published online: 03 Mar 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Albiana Pino, Annamaria Vaccaro & Giuseppe Sandro Mela. (2004) Triptans in migraine. A review of side effects, improvement and recurrence. The Pain Clinic 16:2, pages 115-129.
Read now
Joseph P Yevich. (1997) Antimigraine agents: July 1995 - December 1996. Expert Opinion on Therapeutic Patents 7:5, pages 511-521.
Read now

Articles from other publishers (14)

Carlos M. Villalón & David Centurión. (2007) Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn-Schmiedeberg's Archives of Pharmacology 376:1-2, pages 45-63.
Crossref
Jordi Gras, Jesús Llenas, Josep M. Jansat, José Jáuregui, Xavier Cabarrocas & José M. Palacios. (2006) Almotriptan, a New Anti‐Migraine Agent: A Review. CNS Drug Reviews 8:3, pages 217-234.
Crossref
H‐C Diener & A McHarg. (2000) PHARMACOLOGY AND EFFICACY OF ELETRIPTAN FOR THE TREATMENT OF MIGRAINE ATTACKS. International Journal of Clinical Practice 54:10, pages 670-674.
Crossref
Jordi Gras, Josep Bou, Jesús Llenas, Andrés G Fernández & José M Palacios. (2000) Functional profile of almotriptan in animal models predictive of antimigraine activity. European Journal of Pharmacology 410:1, pages 43-51.
Crossref
Josep Bou, Teresa Domènech, Jaume Puig, Ascensión Heredia, Jordi Gras, Dolors Fernández-Forner, Jorge Beleta & José M. Palacios. (2000) Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. European Journal of Pharmacology 410:1, pages 33-41.
Crossref
Paul Gupta, Paul Butler, Nick B Shepperson & Aileen McHarg. (2000) The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT1B/1D receptor agonist. European Journal of Pharmacology 398:1, pages 73-81.
Crossref
Béla Pete, István Bitter, Kálmán Harsányi & László Tõke. (2000) Synthesis of 5-Substituted Indole Derivatives, Part II. Synthesis of Sumatriptan through the Japp-Klingemann Reaction. HETEROCYCLES 53:3, pages 665.
Crossref
Carolyn Napier, Michael Stewart, Heather Melrose, Brian Hopkins, Aileen McHarg & Rob Wallis. (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of eletriptan binding at human 5-HT1B and 5-HT1D receptors. European Journal of Pharmacology 368:2-3, pages 259-268.
Crossref
Paul Gupta, Jon Scatchard, Carolyn Napier, Aileen McHarg & Rob Wallis. (1999) Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor. European Journal of Pharmacology 367:2-3, pages 283-290.
Crossref
Antoinette MaassenVanDenBrinkMarije ReekersWillem A. BaxMichel D. FerrariPramod R. Saxena. (1998) Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. Circulation 98:1, pages 25-30.
Crossref
Pramod R Saxena, Peter De Vries, Jan P.C Heiligers, Willem A Bax, Antoinette MaassenVanDenBrink & Frank D Yocca. (1998) BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. European Journal of Pharmacology 351:3, pages 329-339.
Crossref
Carlos M. Villalón, Peter de Vries & Pramod R. Saxena. (1997) Serotonin receptors as cardiovascular targets. Drug Discovery Today 2:7, pages 294-300.
Crossref
Pramod R. Saxena, Maassen Antoinette Van Den Brink, Jan P. C. Heiligers, Elizabeth Scalbert & B. Guardiola Lemaǐtre. (2011) Effects of S20749, a Close Analogue of Sumatriptan, on Porcine Carotid Haemodynamics and Human Isolated Coronary Artery. Pharmacology & Toxicology 79:4, pages 199-204.
Crossref
EM Van Gelderen. (2016) Nitroglycerin-Induced Headache. Cephalalgia 16:6, pages 405-406.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.